Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Abbott Laboratories

Start price
Target price
Perf. (%)
€85.17
-
-0.798%

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth > 30% per year expected
Seelos Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.87
€1.00
-0.915%

Could be worthwhile Investment >10% per year
India Globalization Capital

Start price
Target price
Perf. (%)
€3.03
€0.000
-49.873%

Risky Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
overvalued
CytoTools AG

Start price
Target price
Perf. (%)
€10.20
€26.00
1.471%

Could be very worthwhile Investment >20% year
Differentiated customer and product portfolio
Seattle Genetics

Start price
Target price
Perf. (%)
€132.84
€153.00
0.045%

Could be very worthwhile Investment >20% year
Omeros Corp.

Start price
Target price
Perf. (%)
€13.45
€23.00
-14.801%

Could be very worthwhile Investment >20% year
Morphosys AG

Start price
Target price
Perf. (%)
€108.25
€130.00
-0.046%

Verastem Inc.

Start price
Target price
Perf. (%)
€1.30
€3.00
0.000%

Novavax Inc.

Start price
Target price
Perf. (%)
€123.60
-
-15.146%

Achieve Life Sciences Inc.

Start price
Target price
Perf. (%)
€9.61
-
-19.076%

Precipio Inc

Start price
Target price
Perf. (%)
€5.95
€2.00
-55.294%

Alexion Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€89.92
€125.00
-3.270%

Very capable Management
Very good company culture
Leading role in innovation
Could be very worthwhile Investment >20% year
Valbiotis

Start price
Target price
Perf. (%)
-
-
0.000%

Pharma Mar S.A.

Start price
Target price
Perf. (%)
€137.76
-
-35.598%

Pfizer Inc.

Start price
Target price
Perf. (%)
€31.30
€35.00
3.911%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Undervalued
Rigel Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€3.18
-
-36.478%

Rigel Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€3.62
-
-12.155%

Aphria Inc.

Start price
Target price
Perf. (%)
€4.27
€5.85
-5.095%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Fair valuation
Innoviva Inc.

Start price
Target price
Perf. (%)
€12.30
€17.00
-8.130%

Pfizer Inc.

Start price
Target price
Perf. (%)
€30.40
€45.00
-2.303%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Undervalued
PDS Biotechnology Corp.

Start price
Target price
Perf. (%)
€1.73
-
32.948%

Chugai Pharmaceutical Co Ltd

Start price
Target price
Perf. (%)
€49.67
-
-21.879%

Akero Therapeutics Inc

Start price
Target price
Perf. (%)
€22.00
-
35.455%

Immuron

Start price
Target price
Perf. (%)
€14.90
-
-45.638%

HEXO Corp.

Start price
Target price
Perf. (%)
€0.63
€0.75
19.048%